Cargando…

Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021

The 50% plaque reduction neutralization assay (PRNT(50)) has been previously used to assess the neutralization capacity of donor plasma against wild-type and variant of concern (VOC) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Emerging data suggest that plasma with an anti-SARS-CoV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Yi-Chan J., Evans, David H., Robbins, Ninette F., Orjuela, Guillermo, Abe, Kento T., Rathod, Bhavisha, Colwill, Karen, Gingras, Anne-Claude, Tuite, Ashleigh, Yi, Qi-Long, O’Brien, Sheila F., Drews, Steven J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10434250/ https://www.ncbi.nlm.nih.gov/pubmed/37289096 http://dx.doi.org/10.1128/spectrum.05256-22

Ejemplares similares

A Qualitative Comparison of the Abbott SARS-CoV-2 IgG II Quant Assay against Commonly Used Canadian SARS-CoV-2 Enzyme Immunoassays in Blood Donor Retention Specimens, April 2020 to March 2021
por: Abe, Kento T., et al.
Publicado: (2022)

Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays
por: Tuite, Ashleigh R., et al.
Publicado: (2022)

Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses
por: Lin, Yi-Chan J., et al.
Publicado: (2022)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard
por: Saeed, Sahar, et al.
Publicado: (2021)

SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History
por: Drews, Steven J., et al.
Publicado: (2022)

Resistance of SARS‐CoV‐2 beta and gamma variants to plasma collected from Canadian blood donors during the spring of 2020
por: Drews, Steven J., et al.
Publicado: (2021)

Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong, January–March 2022
por: Mefsin, Yonatan M., et al.
Publicado: (2022)

Impact of Omicron BA.1 infection on BA.4/5 immunity in transplant recipients
por: Ferreira, Victor H., et al.
Publicado: (2023)

Projection of healthcare demand in Germany and Switzerland urged by Omicron wave (January–March 2022)
por: Gorji, Hossein, et al.
Publicado: (2023)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

January-March 2009
Publicado: (2009)

January-March 2008
Publicado: (2008)

January-March 2007
Publicado: (2007)

January-March 1997
Publicado: (1997)

January-March 1998
Publicado: (1998)

January-March 1999
Publicado: (1999)

January-March 2001
Publicado: (2001)

January-March 2002
Publicado: (2002)

January-March 2003
Publicado: (2003)

January-March 2005
Publicado: (2005)

January-March 2006
Publicado: (2006)

January-March 1996
Publicado: (1996)

January-March 2010
Publicado: (2010)

Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults
por: Brown, Patrick E., et al.
Publicado: (2022)

Characteristics of the First 284 Patients Infected with the SARS-CoV-2 Omicron BA.2 Subvariant at a Single Center in the Apulia Region of Italy, January–March 2022
por: Loconsole, Daniela, et al.
Publicado: (2022)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Estimating the proportion of Victorians infected with COVID-19 during the Omicron BA.1 epidemic wave of January 2022 in Australia
por: Altermatt, Aimée, et al.
Publicado: (2023)

An Outbreak of the SARS-CoV-2 Omicron Variant BA.1 — Zhuhai City, Guangdong Province, China, January 13, 2022
por: Ruan, Feng, et al.
Publicado: (2022)

Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022
por: Martínez-Baz, Iván, et al.
Publicado: (2023)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages
por: Ai, Jingwen, et al.
Publicado: (2022)

Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease
por: Yau, Kevin, et al.
Publicado: (2023)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

SARS-CoV-2 Omicron sublineage BA.2 replaces BA.1.1: Genomic surveillance in Japan from September 2021 to March 2022
por: Hirotsu, Yosuke, et al.
Publicado: (2022)

COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022
por: Kliker, Limor, et al.
Publicado: (2022)

SARS-CoV-2 self-test uptake and factors associated with self-testing during Omicron BA.1 and BA.2 waves in France, January to May 2022
por: Supplisson, Olivier, et al.
Publicado: (2023)

SARS-CoV-2 Seroprevalence among Canadian Blood Donors: The Advance of Omicron
por: O’Brien, Sheila F., et al.
Publicado: (2022)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2
por: Evans, John P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dru1n7uju7g7oajd4iebp2hlp3